RT Journal Article
SR Electronic
T1 Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e002068
DO 10.1136/jitc-2020-002068
VO 9
IS 3
A1 Melisi, Davide
A1 Oh, Do-Youn
A1 Hollebecque, Antoine
A1 Calvo, Emiliano
A1 Varghese, Anna
A1 Borazanci, Erkut
A1 Macarulla, Teresa
A1 Merz, Valeria
A1 Zecchetto, Camilla
A1 Zhao, Yumin
A1 Gueorguieva, Ivelina
A1 Man, Michael
A1 Gandhi, Leena
A1 Estrem, Shawn T
A1 Benhadji, Karim A
A1 Lanasa, Mark C
A1 Avsar, Emin
A1 Guba, Susan C
A1 Garcia-Carbonero, Rocio
YR 2021
UL http://jitc.bmj.com/content/9/3/e002068.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.